🇺🇸 FDA

P1 · Therapeutic area intelligence

Immunology patent intelligence

Autoimmune, rheumatology, and immunology biologic patents — biosimilar entry timing signals.

Patents
185

Quick answer

185 US pharmaceutical patents in our index match Immunology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 12421302

    CAR-t cells and autoimmune diseases

    The Regents of the University of California · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12403200

    Methods and compositions for treating autoimmune diseases

    Vor Biopharma Inc. · Granted Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12390496

    Methods for treating ulcerative colitis

    Finch Therapeutics Holdings LLC · Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12359204

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Jul 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12297279

    Compositions and methods for treating pain in subjects with rheumatoid arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 13 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12285447

    Methods and compositions for treating ulcerative colitis

    Finch Therapeutics Holdings LLC · Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12246064

    Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12247206

    Soluble interleukin-7 receptor (SIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12213998

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12214015

    Use of c-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Feb 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 30 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12209119

    Method of treating rheumatoid arthritis using antibodies to oxidized phospholipids

    The Regents of the University of California · Granted Tue Jan 28 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12171832

    Methods of treating ulcerative colitis

    Takeda Pharmaceutical Company Limited · Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12116405

    Arthritis treatment

    XBIOTECH INC. · Granted Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12061206

    Diagnosis and treatment of autoimmune diseases

    Takeda Pharmaceutical Company Limited · Granted Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11952419

    Reagents and methods for treating cancer and autoimmune disease

    UNIVERSITY OF CONNECTICUT · Granted Tue Apr 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11932867

    Methods of treating rheumatoid arthritis using RNA-guided genome editing of HLA gene

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11912762

    Method of treating osteoarthritis by administering an anti-connexin 43 antibody

    The Board of Regents of the University of Texas System · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11884731

    Vedolizumab for the treatment of fistulizing Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11807853

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11795216

    Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics

    Takeda Pharmaceutical Company Limited · Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11787840

    Compositions and methods for treating and preventing autoimmune induced cardiac long QT syndrome

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Oct 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11780852

    Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Theravance Biopharma R&D IP, LLC · Granted Tue Oct 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11622991

    Protocol for treatment of lupus nephritis

    AURINIA PHARMACEUTICALS INC. · Granted Tue Apr 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11541075

    Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid

    ANIKA THERAPEUTICS, INC. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11534465

    Fecal matter for treatment of autoimmune diseases

    ACADEMISCH MEDISCH CENTRUM · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11518804

    Method of treating osteoarthritis with an antibody to NGF

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11498969

    Compositions and methods for treating juvenile idiopathic arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11422132

    Peptides and uses thereof for diagnosing and treating myasthenia gravis

    The Regents of the University of California · Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11413303

    Methods for treatment of arthritis

    GALECTIN THERAPEUTICS, INC. · Granted Tue Aug 16 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 11 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11400096

    Small molecules for the treatment of autoimmune disorders

    The Board of Regents of the University of Texas System · Granted Tue Aug 02 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11365221

    Compositions and methods for treating autoimmune and inflammatory disorders

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11319375

    Methods and compositions for treating subjects having rheumatoid arthritis

    REGENERON PHARMACEUTICALS, INC. · Granted Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11304926

    Application of transient receptor potential cation channel TRPV3 in developing drug for preventing or treating psoriasis

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11286279

    Compositions for expanding regulatory T cells (Treg), and treating autoimmune and inflammatory diseases and conditions

    The Regents of the University of California · Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11273182

    Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's disease

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 15 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11230554

    Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

    Rigel Pharmaceuticals, Inc. · Granted Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11220496

    Compounds and method for treating autoimmune diseases

    Rigel Pharmaceuticals, Inc. · Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11202819

    Use of C-type natriuretic peptide variants to treat osteoarthritis

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11192958

    Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

    The Board of Regents of the University of Texas System · Granted Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11166990

    Methods and compositions for treating ulcerative colitis

    Finch Therapeutics Holdings LLC · Granted Tue Nov 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11118186

    Soluble interleukin-7 receptor (sIL7R) modulating therapy to treat autoimmune diseases and cancer

    The Board of Regents of the University of Texas System · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11071759

    Methods for treating ulcerative colitis

    Finch Therapeutics Holdings LLC · Granted Tue Jul 27 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11028129

    Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions

    The Regents of the University of California · Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10947254

    Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10933086

    Composition for preventing, alleviating, or treating arthritis or osteoporosis, containing neoagarooligosaccharide

    DYNEBIO INC. · Granted Tue Mar 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10927435

    Compositions for the treatment of rheumatoid arthritis and methods of using same

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10928391

    CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10907151

    Compositions and methods for treating or preventing lupus

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Immunology patents are indexed?

185 patents match our Immunology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.